Eliza Hawkes
Austin Health
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Eliza Hawkes as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:15 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05788081 · Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.Olivia Newton-John Cancer Research Institute · active not recruiting · Follicular Lymphoma Stage II, Follicular Lymphoma Stage III, Follicular Lymphoma Stage IV · principal investigator
- Ph2NCT04962126 · Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapyOlivia Newton-John Cancer Research Institute · active not recruiting · Follicular Lymphoma · principal investigator
- Ph1NCT03610061 · A Trial of Radiotherapy and Durvalumab in DLBCL and FLAustin Health · completed · Diffuse Large B Cell Lymphoma, Follicular Lymphoma · principal investigator
- Ph1NCT03245021 · Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3ADr. Eliza Hawkes · active not recruiting · Follicular Lymphoma · principal investigator
- Early Ph1NCT03244176 · Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP StudyAustin Health · completed · Lymphomas Non-Hodgkin's B-Cell · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:15 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:15 UTC. The ranking covers the 200 most relevant of 25 PubMed records, and a shared surname and initials can bring in a namesake. All 25 on PubMed
- 454 citationsRCR 12.5
- A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer.J Natl Cancer Inst · 201584 citationsRCR 2.4
- Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial.Ann Oncol · 201772 citationsRCR 2.7
- 59 citationsRCR 2.3
- CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial.Lancet Haematol · 201857 citationsRCR 2.2
- Pembrolizumab in relapsed or refractory Richter syndrome.Br J Haematol · 202047 citationsRCR 1.7
- Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience.Br J Haematol · 202143 citationsRCR 2.5
- 38 citationsRCR 1.2
- Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study.Blood Adv · 202338 citationsRCR 3.4
- Advice on hair and scalp care during cranial radiotherapy: a prospective randomized trial.Radiother Oncol · 200033 citationsRCR 1.2